The role of Src in colon cancer and its therapeutic implications

Chen, Jiezhong, Elfiky, Aymen, Han, Mei, Chen, Chen and Saif, M. Wasif (2014) The role of Src in colon cancer and its therapeutic implications. Clinical Colorectal Cancer, 13 1: 5-13. doi:10.1016/j.clcc.2013.10.003

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Chen, Jiezhong
Elfiky, Aymen
Han, Mei
Chen, Chen
Saif, M. Wasif
Title The role of Src in colon cancer and its therapeutic implications
Journal name Clinical Colorectal Cancer   Check publisher's open access policy
ISSN 1533-0028
Publication date 2014-03-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.clcc.2013.10.003
Open Access Status Not yet assessed
Volume 13
Issue 1
Start page 5
End page 13
Total pages 9
Place of publication New York, United States
Publisher Elsevier
Language eng
Subject 2730 Oncology
2715 Gastroenterology
Abstract Src is a member of a superfamily of membrane-associated nonreceptor protein tyrosine kinases. It is stimulated by receptors of growth hormone, cytokines, and adipokines, and it regulates multiple signaling pathways, including phosphatidylinositide 3 kinase-Akt, mitogen-activated protein kinase, signal transducer and activator of transcription 3, interleukin 8, and vascular endothelial growth factor pathways, and cytoskeletal pathways to cause a cascade of cellular responses. Eighty percent of patients with colon cancer overexpress Src in tumor tissue. Evidence has shown that the overexpression of Src in colon cancer accelerates metastasis and causes chemotherapeutic drug resistance via multiple downstream signaling pathways. Therefore, the inhibition of Src may be useful for the treatment of colon cancer. However, the inhibition of Src may also weaken immune responses that are essential for the eradication of cancer cells. Overcoming the problem of inhibiting Src in cancer cells while retaining immune system efficacy is the key to the successful application of Src-inhibition therapy. Different Src family members are used by the immune system and colon cancer. This differential use may provide a good opportunity to develop Src family member-specific inhibitors to avoid immune inhibition.
Keyword Immune response
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online 13 November 2013

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Biomedical Sciences Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 29 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 19 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 18 Mar 2014, 10:26:54 EST by System User on behalf of School of Biomedical Sciences